Share This

Public company info - The United Laboratories International Holdings Ltd. , 03933.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

The United Laboratories International Holdings Ltd., 03933.HK - Company Profile
Chairman Tsoi Hoi Shan
Share Issued (share) 1,840,000,000
Par Currency Hong Kong Dollar
Par Value 0.01
Industry Medicine
Corporate Profile Business Summary: The Group is Principally engaged in (i) sale of intermediate products (“Intermediate products”); (ii) sale of bulk medicine (“Bulk medicine”); and (iii) sale of antibiotics finished products, nonantibiotics finished products and capsule casings (together “Finished products”). Performance for the year: During the Year, the Group’s revenue amounted to RMB8,392.6 million, representing an increase of approximately 11.7% over 2018. EBITDA was approximately RMB1,798.2 million, representing an increase of 0.5% as compared with last year. Profit attributable to owners of the Company was RMB641.8 million, representing a decrease of 6.0% as compared with last year. Business Review： Intermediate Products and Bulk Medicine The Group’s intermediate products and bulk medicine recorded segment external sales of RMB1,280.4 million and RMB3,593.1 million, respectively, representing year-on-year growth of 3.8% and 6.0% respectively. During first half of the Year, the price of semi-synthetic penicillin bulk medicine fluctuated slightly, and the price of 6-APA gradually decreased to a low level as the market supply capacity recovered, thus resulting impact on revenue and result of intermediate products segment. In respect of export, in the face of the challenges in the international pharmaceutical bulk medicine market and the slower growth of China’s imports and exports, the Group continued to optimise its product mix, deepen its development of global key pharmaceutical markets, and adhered to the international development, resulting in steady growth in export sales. During the year, the Group’s overseas export recorded a sales revenue of RMB2,435.0 million, representing an increase of 23.7% over last year. Finished Products During the year, the Group’s finished products business maintained continued growth and records a segment revenue of approximately RMB3,519.1 million, representing an increase of 21.9%, and segment profit of approximately RMB783.5 million, representing an increase of 27.3%. The increase in segment profits is contributed from change of product mix during the year with increase in sales of products with higher margin. Research and Development The Group has been committed to research and development on a continual basis. The expenditure on R&D for current year amounted to approximately RMB368.0 million representing 29.9% increase as compared with last year. The Group currently has 29 new products under development, which is expected to further enrich the reserve of finished products. In particular, the Group has applied for production of insulin aspart injection and insulin aspart 30 injection and launched clinical trial for liraglutide injection; the clinical trial of insulin degludec injection has been approved in September 2019. Based on the increasingly perfect biological R&D platform, the Group will continue to expand its development of relevant products in the fields of internal secretion and autoimmune disease. With regard to the research and development of chemical pharmaceuticals, the Group remains focus on series of anti-HBV drugs and eye drops, and will continue to expand into new drugs. Prospects: Although the future is subject to greater macro-economic uncertainty, it is expected that China’s pharmaceutical industry will continue to steadily promote the transformation, and the structure of pharmaceutical industry will be further improved, which will leads the industry to the high-quality development stage. The Group will continue to take insulin series as its strategic category, promote further sales growth and improve its market share.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.